1. Home
  2. TBPH vs UIS Comparison

TBPH vs UIS Comparison

Compare TBPH & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • UIS
  • Stock Information
  • Founded
  • TBPH 2013
  • UIS 1942
  • Country
  • TBPH United States
  • UIS United States
  • Employees
  • TBPH N/A
  • UIS N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • UIS EDP Services
  • Sector
  • TBPH Health Care
  • UIS Technology
  • Exchange
  • TBPH Nasdaq
  • UIS Nasdaq
  • Market Cap
  • TBPH 418.7M
  • UIS 474.3M
  • IPO Year
  • TBPH N/A
  • UIS N/A
  • Fundamental
  • Price
  • TBPH $9.47
  • UIS $8.19
  • Analyst Decision
  • TBPH Buy
  • UIS
  • Analyst Count
  • TBPH 4
  • UIS 0
  • Target Price
  • TBPH $13.75
  • UIS N/A
  • AVG Volume (30 Days)
  • TBPH 220.0K
  • UIS 871.8K
  • Earning Date
  • TBPH 11-12-2024
  • UIS 10-29-2024
  • Dividend Yield
  • TBPH N/A
  • UIS N/A
  • EPS Growth
  • TBPH N/A
  • UIS N/A
  • EPS
  • TBPH N/A
  • UIS N/A
  • Revenue
  • TBPH $63,192,000.00
  • UIS $2,020,600,000.00
  • Revenue This Year
  • TBPH $6.93
  • UIS $0.92
  • Revenue Next Year
  • TBPH $45.31
  • UIS $2.90
  • P/E Ratio
  • TBPH N/A
  • UIS N/A
  • Revenue Growth
  • TBPH 15.93
  • UIS 0.29
  • 52 Week Low
  • TBPH $7.44
  • UIS $3.32
  • 52 Week High
  • TBPH $11.71
  • UIS $8.49
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 59.09
  • UIS 64.89
  • Support Level
  • TBPH $9.38
  • UIS $7.13
  • Resistance Level
  • TBPH $10.10
  • UIS $8.42
  • Average True Range (ATR)
  • TBPH 0.35
  • UIS 0.37
  • MACD
  • TBPH 0.06
  • UIS -0.03
  • Stochastic Oscillator
  • TBPH 62.75
  • UIS 77.94

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides solutions that transform digital workplaces securely and create exceptional end-user experiences. CA&I provides digital platform, applications and infrastructure solutions. ECS provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.

Share on Social Networks: